Locating remedies for Alzheimer's disease (AD) is been majorly restricted by inefficiency to establish a definitive detection model for early stage diagnosis of pathological events. This current lapse in AD diagnosis also limits the therapeutic efficiency of the drugs, which might have been effective if given at the earlier stages of the disease. The indicated situation directs towards the burgeoned need for an effective biomarker technique that will help in early detection of AD and would be imminently useful to facilitate improved diagnosis and stimulate therapeutic trials. Till date the major biomarkers, specifically associated with AD detection may help in determining the early stage AD diagnosis and identifying alterations in cellular proteome, offering deeper insight into disease etiology. Currently existing multidisciplinary clinical diagnosis of AD is very tedious, expensive procedure and requires highly trained and skilled professionals who are rarely available outside the specialty clinics. Mutations in amyloid precursor protein (APP) or Presenilin 1 and 2 (PSEN1 and PSEN2) are some biomarkers acting as a critical check points for AD diagnosis. However, the presence of some associated biomarkers in cerebrospinal fluid (CSF) such as total-Tau (tTau), phosphorylated-Tau (pTau) 181 and Amyloid-β (Aβ) 1-42 using structural or functional imaging techniques are considered for confirmatory diagnosis of AD. Further, molecular diagnosis of AD incorporates various sophisticated techniques including immuno-sensing, machine learning, nano conjugation-based detections etc. In current review description, we had summarized the various diagnostic approaches taken and their relevance in mitigating out the long-standing vital urgency of targeted diagnostic tool for detection of AD.

中文翻译：

---

用于阿尔茨海默氏病诊断生物标志物分析的蛋白质组学工具的问世。

由于效率低下，无法为病理事件的早期诊断建立确定的检测模型，阿尔茨海默氏病（AD）的定位疗法受到了很大的限制。AD诊断的这种当前失误也限制了药物的治疗效率，如果在疾病的早期给予该药物可能是有效的。所指示的情况直接导致了对有效生物标志物技术的新兴需求，该技术将有助于AD的早期检测，并且对促进诊断和刺激治疗性试验非常有用。迄今为止，主要的生物标志物，特别是与AD检测有关的标志物，可能有助于确定AD的早期诊断并鉴定细胞蛋白质组的变化，从而提供对疾病病因学的更深入了解。当前，现有的AD多学科临床诊断非常繁琐，昂贵的过程，并且需要训练有素的熟练技术人员，而这些专家在专科门诊以外很少得到。淀粉样蛋白前体蛋白（APP）或早老素1和2（PSEN1和PSEN2）中的突变是一些生物标志物，可作为AD诊断的关键检查点。然而，考虑使用结构或功能成像技术在脑脊液（CSF）中存在一些相关生物标记物，例如总Tau（tTau），磷酸化Tau（pTau）181和淀粉样β（Aβ）1-42。诊断AD。此外，AD的分子诊断结合了各种复杂的技术，包括免疫传感，机器学习，基于纳米共轭的检测等。在当前的综述描述中，